NOVARTIS AG-SPONSORED ADR (NVS) Stock News

JPMorgan's Gori On Trump & 'Incredible' US Economy | Bloomberg The Pulse 01/21

Live from the 2025 World Economic Forum in Davos, we speak to business leaders and central bankers as Donald Trump returns to the White House. JP Morgan's EMEA CEO Filippo Gori says European clients share a split sentiment on the possible outcomes of a second Trump presidency. Also on the show, the Bank of France Governor, Francois Villeroy De Galhau, says the current trend of European disinflation means the ECB may not need to quicken or expand interest rate cuts. Today's guests: Filippo Gori, JP Morgan Chase EMEA CEO & Co-Head of Global Banking; Vas Narasimhan, Novartis CEO; Ron O'Hanley, State Street Chairman & CEO; Francois Villeroy De Galhau, Bank of France Governor (Source: Bloomberg)

Novartis CEO Says Concerns on Trump Health Policy Are Overblown

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are “overblown.”

US appeals court lifts pause on generic version of Novartis' Entresto

Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch. The U.S. Court of Appeals for the District of Columbia Circuit lifted the pause less than 24 hours after it started, potentially freeing MSN to launch its generic in the U.S. amid an ongoing patent dispute between the companies. Spokespeople and an attorney for Novartis did not immediately respond to a request for comment and more information on the ruling.

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Novartis loses emergency bid to block Entresto generic in US

A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug Entresto. The decision by U.S. District Judge Dabney Friedrich clears a hurdle for MSN to introduce the first U.S. generic version of Switzerland-based Novartis' best-selling drug, which brought the company more than $6 billion in revenue in 2023. An attorney and spokespeople for Novartis did not immediately respond to a request for comment.

Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.

Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Balancing Dividends and Fundamentals: The Case of NYSE:NVS.

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

Here's Why Novartis (NVS) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Novartis Says Drug Helps Children With Spinal Atrophy in Study

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma, in an advanced study.

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya. In a 3-0 decision, the 2nd U.S. Circuit Court of Appeals in Manhattan said the whistleblower Steven Camburn can try to prove that Novartis violated the federal False Claims Act by holding "sham" speaker events to boost Gilenya sales. Camburn, a former Novartis sales representative, said the drugmaker paid doctors thousands of dollars and treated them to dinners at high-end restaurants to speak at purportedly educational events that were actually social in nature.

February 2025 Options Now Available For Novartis (NVS)

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected. "In November 2024, we made the decision to close the Morphosys sites in Germany and the U.S. by the end of 2025 and to integrate all portfolio activities into Novartis," WiWo cited Novartis as saying. Novartis did not immediately respond to an emailed request for comment from Reuters.

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog.

Top Stock Reports for Mastercard, Procter & Gamble & Novartis

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter & Gamble Company (PG) and Novartis AG (NVS), as well as two micro-cap stocks, IDT Corporation (IDT) and GSI Technology, Inc. (GSIT).

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.

European Stocks Gain, CAC Rises Ahead of No-Confidence Vote

(Bloomberg) -- European stocks advanced for a fifth consecutive session as German shares hit a fresh record. Investors were watching the no-confidence vote taking place in France. Most Read from BloombergAs Wars Rage, Cities Face a Dark New Era of Urban DestructionRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsThe Stoxx Europe 600 Index rose 0.4% by the close, with retail stocks leading the gains. Spanish retailer Inditex SA jumped to a record high ahead of earnings and Zalando S

Novartis Enters Oversold Territory (NVS)

Why Novartis (NVS) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.